Alteration in cardiac PI3K/Akt/mTOR and ERK signaling pathways with the use of growth hormone and swimming, and the roles of miR21 and miR133

ORKIDE PALABIYIK1, EBRU TASTEKIN2, ZEYNEP BANU DOGANLAR3, PINAR TAYFUR4, AYTEN DOGAN3 and SELMA ARZU VARDAR4

1Department of Medical Services and Techniques, Trakya University Health Services Vocational College; Departments of 2Pathology, 3Medical Biology and 4Physiology, Trakya University Faculty of Medicine, Edirne 22030, Turkey

Received September 10, 2018; Accepted December 5, 2018

DOI: 10.3892/br.2018.1179

Abstract. Athletes misuse recombinant human growth hormone (r-hGH) to enhance their performance. Although r-hGH is known to increase cardiac hypertrophy, the underlying molecular mechanism remains unclear. The aim of the present study was to investigate the role of r-hGH in cardiac intracellular signaling pathways and of miR-21 and miR-133 expression in rat hearts during exercise. A total of 36 adult male Sprague-Dawley rats were divided into sedentary control (SC, n=9), swimming exercise (SE, n=8), r-hGH (GH, n=10) and swimming exercise plus r-hGH (SE-GH, n=9) groups. The exercise groups completed a 1-h swimming exercise 5 times a week for 8 weeks. Subcutaneous r-hGH was administered as 0.3 mg/kg/day. Phosphoinositide-3-kinase (PI3K), serine/threonine protein kinase 1 (AKT1), extracellular signal-regulated kinase (ERK), microRNA (miR)-21 and miR-133 expression was evaluated in ventricular muscle by real-time quantitative polymerase chain reaction. Protein expression of PI3K, AKT1, ERK and mechanistic target of rapamycin (mTOR) was also assessed by immunohistochemistry. Statistical differences were analyzed by two-way ANOVA. PI3K and AKT1 expression and the gene and protein levels was notably increased in the SE-GH group compared with in SC ventricular tissues (P<0.05). mTOR protein expression was higher in the GH, SE and SE-GH groups compared with in the SC group (P<0.05, <0.05 and <0.001, respectively). ERK gene/protein expression was similar across all groups. miR-21 and miR-133 levels in ventricular muscle were higher in the SE and GH groups than those in the SC group. In summary, growth hormone application coupled with swimming exercise appeared to affect the PI3K/AKT/mTOR signaling pathway in the left ventricular tissue of rats; however, ERK signaling pathway appeared inactive in physiological left ventricular hypertrophy caused by swimming and GH administration over 8 weeks. Furthermore, GH treatment resulted in increased miR-21 and miR-133 expression. Future study by our group will aim to assess the effects of higher dose GH treatment.

Introduction

Growth hormone (GH), a 191-amino acid single-chain peptide, is a peptide hormone with anabolic and performance-enhancing effects (1). Direct effects of GH include increasing muscle mass (2) Most of the indirect effects are mediated by induction of insulin-like growth factor 1 (IGF-1) expression in the liver and in peripheral tissues (3). An organ most affected by GH imbalance (deficiency or excess) is the heart (4). Bodybuilders and athletes misuse recombinant human GH (r-hGH) preparations to increase muscle mass and strength; as such, r-hGH has been on the prohibited substances list of the International Federations and the International Olympic Committee since 1989. It is also on the 2010 World Anti-Doping Agency list of prohibited substances (5,6).

Left ventricular hypertrophy resulting from swimming exercise is an important physiological mechanism that increases sarcomeres and cardiac cell growth to compensate for the chronic increase in hemodynamic load (7). Conversely, pathological left ventricular hypertrophy caused by cardiovascular disease is associated with increased fibrosis and decreased aerobic capacity leading to incompatible remodeling in cardiac cells (7). Both in physiological and pathological hypertrophy, intermediate signal transduction pathways in the cytoplasm are triggered via membrane-bound receptors. Signal transduction pathways critical for myosin growth include phosphoinositide-3-kinase (PI3K)/serine/threonine protein kinase (AKT)/mechanistic target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), protein kinase C and nuclear factor of activated T cells pathways, among others (8). In particular, the PI3K/AKT/mTOR signaling pathway has been reported to serve a regulatory role in cell growth, metabolism,
survival and angiogenesis, and to govern the development and transformation of left ventricular hypertrophy (7,9). The ERK signaling pathway, the members of which belong to the MAPK family, comprises a cascade consisting of a series of successively acting kinases that finally results in the phosphorylation and activation of terminal kinases including p38, c-Jun N-terminal kinases and ERK. Following activation, each ERK phosphorylates intracellular targets including transcription factors, resulting in reprogramming of cardiac gene expression (10,11).

MicroRNAs (miRNA/miRs) are small RNA molecules of 18-25 nucleotides which do not encode proteins, and negatively regulate gene expression (12,13). They are involved in the regulation of several physiological responses including cell apoptosis (14), proliferation and differentiation (15). In addition, recent studies have demonstrated that certain miRNAs are involved in cardiovascular diseases and pathological left ventricular hypertrophy (16-18). In particular, miR-21 and miR-133 have been demonstrated to regulate cardiac hypertrophy (17,19). miR-21 has also been implicated in the regulation of cardiac fibrosis and cardiac muscle contractility (20), and has been shown to negatively regulate phosphatase and tensin homolog (PTEN) gene expression (7).

It is established that r-hGH may cause cardiac hypertrophy (6). However, to the best of our knowledge, there is no study demonstrating the mechanism through which r-hGH, together with swimming exercise, affects signaling pathways (PI3K/AKT/mTOR and ERK) that regulate cardiac signaling genes and the miRNAs (miR-21 and miR-133) targeting the genes in these signaling pathways. Thus, the present study aimed to investigate i) the effect of r-hGH and exercise on cardiac PI3K/AKT/mTOR and ERK signaling pathways, and ii) the role of miR-21 and miR-133 expression in ventricular muscle.

Materials and methods

Animals and exercise protocols. A total of 36 male Sprague-Dawley rats (14 weeks old) weighing 200-250 g were obtained from the Experimental Animals Center of Trakya University, Edirne, Turkey. All animals were fed daily with tap water and a standard pellet diet for rats under optimal laboratory conditions (temperature: 22±2°C; humidity: 50-55%; light/dark cycle: 12/12 h). The animals were randomly stratified into sedentary control (SC, n=9), swimming exercise (SE, n=8), r-hGH (GH, n=10) and swimming exercise plus r-hGH (SE-GH, n=9) groups. For 8 weeks, from Monday to Friday, the rats in the SE and SE-GH groups completed a 1-h swimming exercise (7). The swimming pool (120x80x75 cm) was filled with water to a depth of 65 cm. The pool was divided by plastic barriers into twelve lanes. To avoid interaction, each rat was placed into an individual lane. Water temperature was maintained at 31±1°C.

r-hGH was administered subcutaneously 5 days per week for 8 weeks to the animals in the GH and SE-GH groups at a dose of 0.3 (1 IU/day) mg/kg (Humatrope®, Eli Lilly and Company, Indianapolis, IN, USA). The dose was selected based on previous studies (18-21). Animals in the SE-GH group were injected subcutaneously immediately prior to exercise. Saline at the same dose (0.3 mg/kg) was injected subcutaneously to the animals in the SE group.

The study was conducted in the Trakya University Local Experimental Animals Research Center after obtaining approval from the institutional Experimental Animals Ethics Committee (approval no. TUHADYEK:2015/10).

Preparation of samples. After fasting for 24 h following the last exercise, the rats received intraperitoneal thiopental (100 mg/kg) for anesthesia. All rats were sacrificed by cervical dislocation and blood (5 ml) was obtained from the heart for metabolic investigations. Serum was separated from the blood samples via centrifugation at 2,600 x g for 10 min at room temperature, and stored at -20°C to measure IGF-1 and insulin levels at a later time point. Measurement of IGF1 and insulin was performed by means of ELISAs. Isolated hearts were weighed and portions of the left ventricular tissue were stored at -80°C for mRNA and miRNA measurements, and the remaining left ventricular tissue was utilized to create paraffin blocks for immunohistochemical evaluation.

Real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analyses

Total RNA isolation and real-time PCR for mRNA. Total RNA was isolated from the stored left ventricular tissues using a Total RNA PureLink® RNA Mini kit as per the manufacturer’s instructions (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The quantity of extracted RNA was determined with a Qubit® Fluorometer (Invitrogen; Thermo Fisher Scientific, Inc.).

RNA concentrations of the samples were adjusted to 200 ng/µl and cDNA synthesis was performed using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). Gene expression was analyzed by means of RT-qPCR. The PCR cycling conditions were an initial denaturation at 95°C for 5 min followed by 40 cycles at 95°C for 15 sec and 60°C for 45 sec and 72°C for 15 sec. The primers, sequences of which are provided in Table I, were used with SYBR® Select Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) to determine the changes in gene expression. Gene expressions were determined as the relative fold change compared with the control group, and normalized to β-actin mRNA expression.

TaqMan miRNA assay and real-time PCR for miRNA. miRNA isolation from left ventricular tissues was performed
with a mirVana miRNA Isolation kit (Ambion) as per the manufacturer's instructions. cDNA for miRNA analysis was synthesized from total RNA utilizing gene-specific primers according to the TaqMan MicroRNA Reverse Transcription Assay protocol (Applied Biosystems; Thermo Fisher Scientific, Inc.). The 15 µl reactions obtained by the TaqMan MicroRNA Reverse Transcription kit protocol were incubated in a thermal cycler (10 min at 95˚C followed by 40 cycles of 15 sec at 95˚C, 1 min at 60˚C and 15 sec at 72˚C). PCR quantification was performed by means of a TaqMan MicroRNA Assay (Thermo Fisher Scientific, Inc.) protocol. The probe mix from the TaqMan MicroRNA Assay protocol contained sequences for miR-21 and -133 (Taqman MicroRNA Assay 002393 and 002246; Thermo Fisher Scientific, Inc.). Samples were normalized by evaluating against U6 gene expression (TaqMan MicroRNA Assay 001973).

Quantification. PCR product generation was monitored by measuring the increase in fluorescence caused by probe presence in the TaqMan MicroRNA Assay at each annealing phase or by measuring the increase in fluorescence caused by probe presence in the Thermo Fisher Scientific protocol. The 15 µl reactions obtained by the TaqMan MicroRNA Reverse Transcription kit protocol were incubated in a thermal cycler (10 min at 95˚C followed by 40 cycles of 15 sec at 95˚C, 1 min at 60˚C and 15 sec at 72˚C). PCR quantification was performed by means of a TaqMan MicroRNA Assay (Thermo Fisher Scientific, Inc.) protocol. The probe mix from the TaqMan MicroRNA Assay protocol contained sequences for miR-21 and -133 (Taqman MicroRNA Assay 002393 and 002246; Thermo Fisher Scientific, Inc.). Samples were normalized by evaluating against U6 gene expression (TaqMan MicroRNA Assay 001973).

**Table 1. Quantitative real-time polymerase chain reaction primers.**

| Gene  | Sequence, 5'-3' |
|-------|----------------|
| PI3K  | F: CATGGATGCTTTGCAAGGGTTT R: CCAGATTTCTTCCATGATTTGGA |
| PTEN  | F: AGACCCAATCCACCAACACG R: TACACAGCCGCTTCCTTTCC |
| AKT1  | F: ACGACTTTGAGGGGTAGAG R: CAACTTGCACTGTGTAACCG |
| ERK1/2| F: GAGCCCAAGGGAATCCTGCTG R: TGGAGCCGGGCGCTGTCTC |
| ANP   | F: CTTCGGGATGTAGATGAC R: CTTGGGATCTTTTGCGATG |
| β-MHC | F: CATCCCCATGAGACGGAAG R: AGGCTCTTCCTGCTGGAC |
| β-actin| F: AGAGGGAAATCCGTGCGTAC R: AGGAAAGGAAGGCTGGAGAGA |

PI3K, phosphoinositide-3-kinase; PTEN, phosphatase and tensin homolog; AKT1, serine/threonine protein kinase 1; ERK1/2, extra-cellular signal-regulated kinase; ANP, atrial natriuretic polypeptide; MHC, myosin heavy chain; F, forward; R, reverse.

ELISA measurements. The stored serum samples were evaluated using ELISA kits for IGF-1 (Rat IGF-1, cat no. EK0377; Wuhan Boster Biological Technology, Ltd., Wuhan, China) and insulin (Rat/Mouse insulin, cat no. EZRMI-13K; EMD Millipore, Billerica, MA, USA) as per the manufacturer's instructions.

In the experimental procedure for IGF-1 measurement, a standard sandwich technique involving enzyme-linked immunosorbent technology was used. Absorbance was measured at 450 nm with an ELISA reader (FL 800; BioTek Instruments, Inc., Winooski, VT, USA). The IGF-1 assay sensitivity was <5 pg/ml and the range of the assay was 62.5-4000 pg/ml.

In the experimental procedure for insulin measurement, a double-antibody sandwich enzyme-linked immunosorbent assay was used to determine insulin level in the samples. Absorbance was measured at 450 nm with the ELISA reader. The insulin assay sensitivity was 0.2 ng/ml (17.5 pM for a sample volume of 10 µl) and the appropriate range of the assay was 0.2-10 ng/ml.

Two repeats were performed.

**Immunohistochemical method and evaluation.** Left ventricular tissue samples were fixed for 24 h at room temperature in 10% formalin solution. The samples were subsequently passed through an ascending ethyl alcohol series (60.0-70.0-80.0-90.0-99.9%). The tissues were exposed to two changes of xylene for transparency and then embedded in paraffin. Following deparaffinization of 5-µm sections from the blocks, one section of each block was stained with hematoxylin and eosin (H&E) stain for general histological examination of the tissues. Counterstaining was performed with Hematoxylin for 3-5 min at room temperature and eosin for different time periods under visual control. For the other sections, a Ventana BenchMark XT Automated IHC/ISH slide staining system (Ventana Medical Systems, Inc., Tucson, AZ, USA) was used to apply immunohistological stains against the following: PI3K catalytic subunit α (polypeptide p110; PIK3CA; cat no. 09-482), PTEN (cat. no. 09-035), AKT1 (p-phosphorylated (p)-AKT Ser473), cat no. 07-1398), p-mTOR (p-mTOR Ser2448 catalytic domain, cat no. 07-1415; all from EMD Millipore) and ERK1/2 (p-ERK1/2 Thr202/Thr204; cat no. 4370S; Cell Signaling Technology, Inc., Danvers, MA, USA).

Immunohistochemical scoring was conducted in a manner entirely blinded to all clinical and biological variables (24). PIK3CA staining was scored on the following scale: 0, no staining; 1+, staining <50%; 2+, staining ≥50% with weak intensity; 3+, ≥50% staining with strong intensity (25).

PTEN expression was scored independently based on the intensity and extent of staining. The intensity of positive staining was scored from 0 to 2 as follows: 0 (none), 1 (weak; intensity < positive control), 2 (strong; intensity ≥ positive control). Positive staining was assessed using a semi-quantitative grading system consisting of five categories: 0, <5% positive cells; 1, 6-25% positive cells; 2, 26-50% positive cells; 3, 51-75% positive cells; 4, 76-100% positive cells. The sum of the two values provided the total score, and a score ≤4 was considered PTEN-negative (26).

p-AKT, p-mTOR and ERK levels were stratified into three categories based on staining intensity as well as posi-
Table II. Effects of r-hGH and exercise on physiological properties and metabolic parameters in rats.

| Parameters              | SC (n=10)       | SE (n=8)       | GH (n=10)       | SE-GH (n=9)     | P-value* |
|------------------------|-----------------|----------------|-----------------|-----------------|----------|
| BW, g                  | 307.80±6.34     | 269.38±7.09    | 281.50±6.34     | 275.11±6.69     | <0.05    |
| HWI                    | 3.64±0.03       | 4.21±0.07      | 4.02±0.06       | 4.40±0.07       | <0.001   |
| LVWT, mm               | 3.09±0.06       | 3.13±0.06      | 3.14±0.05       | 3.23±0.08       | 0.23     |
| Insulin, mIU/l         | 0.68±0.13       | 0.44±0.08      | 0.58±0.12       | 0.57±0.11       | 0.39     |
| IGF-1, pg/ml           | 5,736.05±306.62 | 6,410.46±226.46| 6,260.12±202.55| 5,922.10±142.87| 0.69     |

Data are presented as the mean ± standard error of the mean. * Compared with SC. BW, body weight; HWI, heart weight index (heart weight/ body weight x1,000 g/g); LVWT, left ventricular wall thickness; IGF-1, insulin-like growth hormone-1; SC, sedentary control; SE, swimming exercise; GH, r-hGH exposure; SE-GH, swimming exercise-r-hGH exposure; r-hGH, recombinant human growth hormone.

Results

Clinical characteristics. Results of all physiological and metabolic parameters of the study evaluating the effects of r-hGH administration and swimming exercise are presented in Table II. Comparison of heart weights revealed an increase in the SE-GH group compared with in the SC group (P<0.05). This significant difference was deemed to result from the swimming exercise and r-hGH administration. In terms of left ventricular weight, this was significantly increased in the SE-GH group compared with in the SC group (P<0.05). Significant increases were also observed in the SE and GH groups (4.30- and 3.67-fold, P<0.05) and decreased in the SE group (0.34-fold, P<0.05) compared with in the control group (Fig. 1; α-MHC and α-actin not shown).

Molecular markers of left ventricular hypertrophy. Atrial natriuretic peptide (ANP), the two forms of myosin heavy chain (α-MHC and β-MHC) and α-actin, which are considered as molecular markers of cardiac hypertrophy (29), were evaluated. There was a significant increase in ANP expression in the SE-GH group compared with in the SC group (3.20-fold, P<0.05). β-MHC was increased in the SE-GH group (6.76-fold, P<0.05) and decreased in the SE group (0.44-fold, P<0.05) compared with in the control group (Fig. 2).

AKT-1 gene expression, which is involved in the regulation of protein synthesis and is a major suppressor of PI3K (7), was significantly increased in the SE-GH group (5.98-fold, P<0.05) compared with in the SC group. Significant increases were also observed in the SE and GH groups (4.30- and 3.67-fold, P<0.05). PTEN is a major negative regulator of PI3K gene expression (7). The present data demonstrated that PTEN was significantly decreased in the SE group (0.44-fold, P<0.05) compared with in the SC group; while no significant difference was indicated when the two GH-treated groups were compared with the SC group (Fig. 2).

Gene expression of ERK1/2 was unchanged with exercise and/or r-hGH administration and remained comparable across all groups (Fig. 2).

Immunohistochemical results. PI3Kα staining grades were significantly different across the groups. The difference was a result of significantly increased PI3K staining in left ventricular tissue of the SE, GH and SE-GH groups compared with that in the SC group (Fig. 3). PTEN staining grades were similar across all groups (not shown).

In terms of AKT, the groups revealed statistically significant differences, with increased p-AKT-1 in the GH and SE-GH groups compared with in the SC group (P<0.05). Regarding p-mTOR, significant increases were observed in all...
test groups [SE (P<0.05), GH (P<0.05) and SE-GH (P<0.01)] compared with SC (Fig. 3).

No significant differences were noted in ERK1/2 protein levels across the groups (not shown).

**miRNA analysis.** miR-21 gene expression was determined to be increased in the SE and GH groups, compared with the SC group (P<0.05). When miR-133 levels were compared, significant increases were observed in the SE and GH groups relative to levels in the SC group (P<0.05). Expression levels of miR-21/133 in the SE-GH group did not exhibit any significant change compared with those in the SC group (Fig. 4).

**Discussion**

It is known to use r-hGH to improve performance and muscle mass by some athletes (30). However, no study to our knowledge has demonstrated the mechanism through which r-hGH, together with swimming exercise, may affect signaling pathways (PI3K/AKT/mTOR and ERK) that regulate cardiac signaling genes and associated miRNAs (miR-21 and miR-133) (31). A key finding of the present study was the altered expression of genes in the PI3K/AKT/mTOR signaling pathway with r-hGH administration and swimming exercise. With this, the present study demonstrated
that r-hGH administration may trigger the similar signal transduction pathways in ventricular muscle. However, no change was detected between the groups in terms of ERK1/2 gene expression, which is involved in the ERK signaling pathway that is active during cardiac pathological hypertrophy (Fig. 5).

Dissimilar to the present study, previous studies planned GH administration based on the therapeutic approach in children or adults with GH deficiency (4). Various studies have been performed on the use of r-hGH as a doping hormone in sports (5,6). However, the present study is seemingly the first to investigate the effects of r-hGH administration in conjunction with swimming exercise on PI3K/AKT/mTOR and ERK signaling pathways, known to regulate cardiac hypertrophy, and on miRNAs associated with cardiac hypertrophy (miR-21 and miR-133) in rats. In the present study, r-hGH was administered at 0.3 mg/kg (1 IU/day) concurrently with swimming exercise 5 times a week for 8 weeks.

A limitation of the current study is the evaluation of one dose level, when different doses may demonstrate the potential harmful effects of r-hGH. We plan to assess the effects of higher dose r-hGH treatment in the future.

Heart weight/body weight, myocyte diameter and sedentary bradycardia are among the determinants of physiological left ventricular hypertrophy (7,22,28). The current study data demonstrated left ventricular hypertrophy formation based on increase in to heart weight/body weight ratio (HWI) in SE and SE-GH rats.
ANP, β-MHC and α-actin levels have been reported as molecular markers of pathological hypertrophy (32,33). Increased expression of ANP and β-MHC was found in the SE-GH group in the current study; while relatively small changes were determined in ANP gene expression. No changes in these factors were identified in the SE and GH groups. It is noteworthy that markedly greater increases in ANP gene expression have been reported under conditions of acute pressure or volume overload (10- to 20-fold increase), which may represent a different pathogenetic response (29).

Previous studies have shown that activation of the PI3K/AKT signaling cascade results in myocardial hypertrophy (33,34). In a cardiac hypertrophy study utilizing aortic narrowing surgery, PI3K-negative transgenic mice (dnPI3K) were determined to have smaller hearts (appearance and weight) compared with controls. Additionally, a significant increase in heart weight was observed among dNPI3K mice compared with the control group in response to placement of an aortic band and swimming exercise (8). However, it has been suggested that PI3K signaling is not essential for pathological hypertrophy development induced by increased pressure, but is important for physiological cardiac hypertrophy development induced by swimming exercise (34). In the present study, PI3K gene and PI3Kα protein expression levels were increased to a greater extent in the SE-GH group compared with levels in the other groups. Furthermore, HWI values were significantly higher in the SE-GH group. This increase appeared to be a result of both the swimming exercise and r-hGH administration. This
suggests that r-hGH administration for 8 weeks does not cause as much damage as pathological cardiac hypertrophy induced by an aortic band, but differs from the physiological hypertrophy induced by swimming exercise. Greater understanding of the mechanism involved requires further studies performed with higher doses of r-hGH over longer durations.

PTEN is established as a major negative regulator of the PI3K/AKT signaling pathway (35). Interestingly, heart weight has been reported to be increased (by 50%) in PTEN (null) rats (36). Certain studies have demonstrated negative regulation of PTEN gene expression by miR-21 (31). miR-21 has also been shown to serve a role in cardiomyocyte hypertrophy (37). In a study by Ma et al (7), PTEN expression was significantly decreased at the gene and protein levels in the SE group compared with in the control group, and the expression of PTEN-targeting miR-21 was also observed to be significantly increased. Similarly, in the present study, a significant decrease in PTEN was observed in the SE group compared with in the control group, concomitant with a significant increase in miR-21 gene expression. However, in the GH and SE-GH groups, no difference was observed in PTEN gene expression compared with the control, while miR-21 was significantly increased in the GH group; the miR-21 expression was similar to that of controls in the SE-GH group. These findings suggest that r-hGH administration may impair the regulation between miR-21 and its target PTEN.

AKT-1 has been demonstrated to be necessary for the development of physiological hypertrophy induced by exercise (38) and for the regulation of normal cardiac growth (39). Previous reports have concluded that cardiac AKT-1 may regulate cardiac hypertrophy when studying models of cardiac hypertrophy or ischemia (32,38). In the study of Ma et al (7), it was concluded that AKT1 upregulated PI3Kα through phosphorylation in left ventricular hypertrophy induced by swimming exercise. Left ventricular hypertrophy (LVH) induced by swimming exercise training is an important physiological mechanism that compensates for chronic increases in hemodynamics (7). Its comparison to the previously reported Akt2 deficiency phenotype reveals the non-redundant functions of Akt1 and Akt2 genes with respect to organismal growth and insulin-regulated glucose metabolism (39). To assess the role of AKT1, the present study tested AKT1 gene and p-AKT1 protein expression. A significant increase in AKT1 gene expression was observed in the SE-GH group compared with in the controls, and p-AKT1 protein levels were significantly higher in the GH and SE-GH groups than in the control group. This demonstrates that AKT1 may increase the upregulation of PI3Kα and result in the relatively highest elevation in PI3K gene expression observed in the SE-GH group. Expression of the mTOR gene has been associated with decreased cardiac hypertrophy through inhibition of mTOR with rapamycin in humans and animal models (34,40). In the current study, phosphoSer2448 mTOR protein expression was determined to be increased in SE, GH and SE-GH rats compared with in controls. These results may aid in clarifying the cause of hypertrophy following SE-GH exposure.

It has been reported that the activation of cardiac myocytes in response to any stress stimulation occurs by means of the ERK1/2 signaling pathway (8). Exercise and pressure overload may activate the ERK1/2 signaling pathway (10,39). Another study has suggested that the hypertrophic response to exercise-induced load increase is not reduced, although phosphorylation of ERK1/2 is essentially eliminated, following the stimulation of increased pressure (40,41). Additionally, it has been reported that MAPK kinase-ERK1/2 inhibition does interfere with hypertrophic morphology (19). In the present study, it was observed that post-exercise development of left ventricular hypertrophy did not differ between the groups in terms of ERK1/2 signaling: ERK1/2 gene and protein expression was similar across all groups. With this, the data indicates that the ERK1/2 signaling pathway may not be activated during physiological left ventricular hypertrophy caused by swimming exercise and r-hGH administration over 8 weeks.

miR-133, which is established to be highly expressed in adult heart and skeletal muscles, serves a role in cell differentiation and proliferation (42,43). miR-133 has a critical role in determining cardiomyocyte hypertrophy; its overexpression may inhibit hypertrophy whereas its suppression may induces hypertrophy in vitro and in vivo (20). Previous study has shown that miR-133 may controls cardiac hypertrophy and decrease significantly in the presence of cardiac hypertrophy and heart failure (44). Thus, the reduction of miR-133 expression may be involved in the development and progression of chronic heart failure (45). The present study identified increased miR-133 expression in the ventricular tissue of SE and GH rats compared with controls. However, the SE-GH group was similar to the controls with regard to miR-133 expression.

In conclusion, the present study demonstrated that r-hGH administration with swimming exercise over 8 weeks altered PI3K, PTEN, AKT-1 and mTOR expression in rat heart. As these factors are involved in the PI3K/AKT/mTOR signaling pathway, as a major regulator of cell proliferation, metabolism, survival and angiogenesis, these changes may have contributed to cardiac hypertrophy. Additionally, r-hGH administration was observed to impair the negative regulation between miR-21 and its target, PTEN. Greater understanding of this mechanism requires further studies on more genes and miRNAs involved in the PI3K/AKT/mTOR and ERK signaling pathways.

Acknowledgments

Not applicable.

Funding

The current study was funded by Trakya University Scientific Research Projects Unit (Project no. 2015-36; Edirne, Turkey).

Availability of data and materials

The materials and data described in the manuscript are available on reasonable request for non-commercial purposes.

Authors’ contributions

OP designed the experiments, and coordinated the project and interpreted results. SAV interpreted the results. ET was responsible for morphological evaluations and interpretation of results. PT and AD were involved in the animal protocols and determination of blood parameters.
Et al β - /
17. 16. 14. 13. 12. 11. 8. 6. 4. 3. 1. 2. 3.
References
The authors declare that they have no competing interests.

1. Graham MR, Baker JS, Evans P, Kicman A, Cowan D, Hullin D, Thomas N and Davies B: Physical effects of short-term recombinant human growth hormone administration in abstinence steroid dependency. Horm Res 69: 343-354, 2008.
2. Jenkins PJ: Growth hormone and exercise. Clin Endocrinol (Oxf) 50: 683-689, 1999.
3. Castellano G, Affuso F, Conza PD and Fazio S: The GH/IGF-1 Axis and Heart Failure. Curr Cardiol Rev 5: 203-215, 2009.
4. Colao A, Marzullo P, Di Somma C and Lombardi G: Growth hormone and the heart. Clin Endocrinol (Oxf) 54: 137-154, 2001.
5. World Anti-Doping Agency: The 2010 Prohibited List International Standard. https://www.wada-ama.org/sites/default/files/resources/files/WADA_Prohibited_List_2010_EN.pdf. Accessed September 19, 2009.
6. Voss SC, Giraud S, Alsaryraf M, Bourdon PC, Schumacher YO, Fluck M, Mather K, Mather J, Li K: MicroRNA-21 Regulates PI3K-PTEN signaling pathway. Eur J Appl Physiol 113: 2473-2486, 2013.
7. Heineke J and Molkentin JD: Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7: 589-600, 2006.
8. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
9. Sutherland G and Clark A: ‘Stress-responsive’ mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 83: 345-352, 1998.
10. Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, Robbins J and Molkentin JD: Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 104: 14074-14079, 2007.
11. Hutfvud G and Zamore PD: A microRNA in a multiple-turnover RNAi enzyme complex. Science 297: 2056-2060, 2002.
12. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
13. Bao H, Hu S, Zhang C, Shi S, Qin W, Zeng C, Zen K and Liu Z: Inhibition of miRNA-21 prevents fibrogenic activation in podocytes and tubular cells in IgA nephropathy. Biochem Biophys Res Commun 444: 455-460, 2014.
14. Da Costa Martins PA and De Windt LJ: Targeting microRNA targets. Circ Res 111: 506-508, 2012.
15. Cheng YS, Tang YQ, Dai DZ and Dai Y: AQP4 knockout mice manifest abnormal expressions of calcium handling proteins possibly due to exacerbating pro-inflammatory factors in the heart. Biochem Pharmacol 83: 97-105, 2012.
16. Da Costa Martins PA and De Windt LJ: MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res 93: 563-572, 2012.
17. Wang L, Li X, Zhou Y, Shi H, Xu C, He H, Wang S, Xiong X, Zhang Y, Du Z, et al: Downregulation of miR-133 via MAPK/ERK signaling pathway involved in nicotine-induced cardiomyocyte apoptosis. Naunyn Schmiedebergs Arch Pharmacol 387: 197-206, 2014.
18. Dong DL, Chen C, Luo R, Wang N, Li Z, Tu YJ, Hu JT, Chu X, Huang W and Yang BF: Reciprocal repression between microRNA-133 and calciumregulates cardiac hypertrophy: A novel mechanism for integrative cardiac hypertrophy. Hypertension 55: 946-952, 2010.
19. Dong S, Ma W, Hao B, Hu F, Yan L, Yan X, Wang Y, Chen Z and Wang Z: microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol 7: 565-574, 2014.
20. De Silva ND Jr, Fernandes T, Soci UP, Monteiro AW, Phillips MI and DE Oliveira EM: Swimming training in rats increases cardiac MicroRNA-126 expression and angiogenesis. Med Sci Sports Exerc 44: 1453-1462, 2012.
21. Oliveira EM, Sasaki MS, Cerêncio M, Baraúna VG and Kocher JE: Local renin-angiotensin system regulates left ventricular hypertrophy induced by swimming training independent of circulating renin: A pharmacological study. J Renin Angiotensin Aldosterone Syst 10: 15-23, 2009.
22. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔCt) method. Methods 25: 402-408, 2001.
23. Hirata Y, Murai N, Yanaihara N, Saito M, Saito M, Urashima M, Murakami Y, Matsuufuji S and Okamoto A: MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma. BMC Cancer 14: 799, 2014.
24. Eljine K, Yeik M, Atila Ibi S, Takeuchi S, Mikami I, Koizumi K, Usuda J and Gemma A: Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma. Int J Oncol 46: 505-512, 2015.
25. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Wang W, Smith Shi D and Yu D: Activation of the Akt/mammalian target of rapamycin4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788, 2004.
26. Domenighetti AA, Danes VR, Culf CL, Pavaloro JM, Proietto J and Delbridge LM: Targeted GLUT-4 deficiency in the heart; induces cardiomyocyte hypertrophy and impaired contractility linked with Ca(2+) and proton flux dysregulation. J Mol Cell Cardiol 48: 663-672, 2010.
27. Chung E and Diffee GM: Effect of aging on power output properties in rat skinned cardiac myocytes. J Gerontol A Biol Sci Med Sci 66: 1267-1275, 2011.
28. Vikstrom KL, Bohlmeyer T, Factor SM and Leinwand LA: Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ Res 82: 773-778, 1998.
29. Saugy M, Robinson N, Saudan C, Baune M, Avois L and Mangin P: Human growth hormone doping in sport. Br J Sports Med 40 (Suppl 1): i35-139, 2006.
30. Cheng Y, Ji R, Yue Y, Yang J, Liu X, Chen H, Dean DB and Zhang C: MicroRNAs are aberrantly expressed in hypertrophic heart: Do they play a role in cardiac hypertrophy? Am J Pathol 170: 1831-1840, 2007.
31. Soci UP, Fernandes T, Hashimoto NY, Mota GF, Amadeu MA, Rosa KT, Iriogoyen MC, Phillips MI and Oliveira EM: MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats. Physiol Genomics 43: 665-673, 2011.
32. McMullen JR and Jennings GL: Differences between pathological and physiological cardiac hypertrophy: Novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 34: 255-262, 2007.
33. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang JM and Izumo S: Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100: 12355-12360, 2003.
34. Maehama T and Dixon JE: PTEN: A tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 9: 125-128, 1999.
35. Crackower MA, Oudit GY, Koziarzdzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-SasakI J, et al: Regulation of myocardial contractility and cell size by distinct PI(3)K-PTEN signaling pathways. Cell 110: 737-749, 2002.
39. Cho H, Thorvaldsen JL, Chu Q, Feng F and Birnbaum MJ: Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276: 38349-38352, 2001.

40. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ and Izumo S: Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107: 1664-1670, 2003.

41. Leontieva OV, Paszkiewicz GM and Blagosklonny MV: Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY) 4: 899-916, 2012.

42. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL and Wang DZ: The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38: 228-233, 2006.

43. Horie T, Ono K, Nishi H, Iwanaga Y, Nagao K, Kinoshita M, Kuwabara Y, Takanabe R, Hasegawa K, Kita T, et al: MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem Biophys Res Commun 389: 315-320, 2009.

44. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA and Olson EN: A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103: 18255-18260, 2006.

45. Abdellatif M: The role of microRNA-133 in cardiac hypertrophy uncovered. Circ Res 106: 16-18, 2010.